LMB-2 depleted allogeneic donor T cells

LMB-2 depleted allogeneic donor T cells is an experimental cellular therapy designed to prevent graft-versus-host disease (GvHD) while maintaining graft-versus-tumor (GvT) effects in patients undergoing hematopoietic stem cell transplantation. The product is created by incubating donor T cells with recipient stimulator cells *ex vivo* to induce the activation of alloreactive T lymphocytes, which then upregulate the Interleukin-2 receptor alpha chain (CD25). These activated cells are selectively eliminated using LMB-2, a recombinant immunotoxin consisting of a single-chain variable fragment (scFv) directed against CD25 fused to a truncated version of Pseudomonas exotoxin (PE38). The resulting cell population, depleted of GvHD-causing alloreactive cells but retaining a broad repertoire of T cells reactive against pathogens and tumor antigens, is then infused into the patient. This approach aims to reduce the incidence and severity of GvHD without the broad immunosuppression typically associated with global T-cell depletion.

Other names

CD25-depleted allogeneic T cellsCD-25-depleted allogeneic T cellsCD 25-depleted allogeneic T cellsAnti-CD25 immunotoxin-depleted donor lymphocytesAnti-CD-25 immunotoxin-depleted donor lymphocytesAnti-CD 25 immunotoxin-depleted donor lymphocytesAnti-Tac(Fv)-PE38 depleted T cells